Recruiting

Testing a new cancer treatment given alone or with standard therapy

Plain-English translation of NCT07086768 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated September 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called to see if it can help people with advanced or spreading solid tumors. The study will first test the medication on its own in different doses to find the safest level. Then it will test this medication combined with an approved cancer drug called T-DXd in patients whose tumors have a specific marker (HER2 positive).

This medication is being tested because current standard treatments don't work well enough for everyone with advanced solid tumors, and researchers believe this new approach may help patients whose cancer has stopped responding to existing therapies.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with advanced or spreading solid tumors that have not responded to or stopped responding to standard cancer treatment
you are in good enough overall health (ECOG performance status 0 or 1) to participate in the study
you have a life expectancy of at least 12 weeks
your heart function is normal (left ventricular ejection fraction at least 50%)
your blood counts and organ function meet the study requirements

You likely don't qualify if…

you are allergic to monoclonal antibodies or the components of this medication
you have previously received treatment with other drugs targeting similar pathways (SIRPα or CD47 targeting agents)
you have an active autoimmune disease or a history of autoimmune disease requiring steroids or immunosuppressive medications
you have received cancer treatment within 4 weeks before enrollment (or 5 half-lives, whichever is shorter)

What participation looks like

You will receive the study medication as an intravenous infusion on the first day of each 21-day treatment cycle. Depending on which group you are assigned to, you may receive the medication alone at different dose levels, or combined with the standard approved therapy. You will need to visit the clinic regularly for blood tests, imaging scans, and heart function checks to monitor how well the treatment is working and watch for any side effects.

AI-generated summary from trial data · Sep 6, 2026 · Not medical advice

Trial locations(1 site)

United States

University of Texas Health Science Center at San Antonio, San Antonio, Texas